Theratechnologies Inc

THTX

3.390USD

0.000

Close 11/06, 16:00（ET）Quotes delayed by 15 min

Theratechnologies Inc's Score

Industry at a Glance

Industry Ranking

95 / 175

Overall Ranking

236 / 4715

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

--

Current Rating

7.250

Target Price

+113.86%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Theratechnologies Inc Highlights

StrengthsRisks

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

Growing

The company is in a growing phase, with the latest annual income totaling USD 85.87M.

Undervalued

The company’s latest PE is -18.27, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 22.32M shares, decreasing 4.58% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.45.

Its latest quarterly revenue reached 17.73M, representing a year-over-year decrease of 19.48%, while its net profit experienced a year-over-year decrease of 552.08%.

Score

Industry at a Glance

Previous score

7.16

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

The company’s current valuation score is 4.00, which is lower than the Pharmaceuticals industry's average of 4.88. Its current P/E ratio is -18.27, which is -89.40% below the recent high of -1.94 and 39.54% above the recent low of -11.05.

Score

Industry at a Glance

Previous score

1.20

Change

2.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 95/175

No Data

The company’s current earnings forecast score is 7.00, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Theratechnologies Inc is 3.80, with a high of 3.80 and a low of 3.80.

Score

Industry at a Glance

Previous score

7.00

Change

0

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 6.54, which is higher than the Pharmaceuticals industry's average of 6.44. Sideways: Currently, the stock price is trading between the resistance level at 3.45 and the support level at 3.29, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.47

Change

0.07

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-09-25

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Worth Venture Partners, LLC

533.40K

-7.54%

National Bank of Canada

222.87K

+13.09%

Stonepine Capital Management, LLC

189.05K

+632.05%

SEB Investment Management AB

132.64K

--

Dimensional Fund Advisors, L.P.

107.48K

+260.12%

Harbour Investments, Inc

96.04K

-0.07%

Susquehanna International Group, LLP

80.67K

--

Stifel, Nicolaus & Company, Incorporated

79.60K

-0.62%



1

2



The company’s current risk assessment score is 4.85, which is higher than the Pharmaceuticals industry's average of 4.09. The company's beta value is 0.76. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Theratechnologies Inc

THTX

5.88 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.79 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ligand Pharmaceuticals Inc

LGND

8.74 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Innoviva Inc

INVA

8.68 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Collegium Pharmaceutical Inc

COLL

8.68 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.59 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment